{"id":"W83713607","doi":"10.2165/11587890-000000000-00000","title":"The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis","year":2011,"lang":"en","type":"review","venue":"American Journal of Clinical Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":74,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research; Western University","funders":"Allergan; Genentech; LEO Pharma; Medac; Mitsubishi Tanabe Pharma Corporation; Cilag; Astellas Pharma; Novo Nordisk; Incyte; University of Connecticut; Abbott Laboratories; Zalicus; Biogen; Celgene; Amgen; Pfizer; Galderma; Eli Lilly and Company; GlaxoSmithKline; Eisai","keywords":"Adalimumab; Medicine; Adverse effect; Psoriasis; Placebo; Population; Clinical trial; Internal medicine; Dosing; Incidence (geometry); Dermatology; Pathology; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001069177,0.000503634,0.001977418,0.0006974476,0.0001646236,0.0008650413,0.0009240914,0.0008793519,0.001630456],"category_scores_gemma":[0.001063776,0.0001939345,0.0007143925,0.0007457756,0.000345297,0.0006333774,0.0002784188,0.001455175,0.0008112705],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003877864,"about_ca_system_score_gemma":0.000653048,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005560915,"about_ca_topic_score_gemma":0.001366579,"domain_scores_codex":[0.9997022,0.00005761527,0.00006398977,0.00004233295,0.0001097079,0.00002413723],"domain_scores_gemma":[0.9992951,0.0003838577,0.0001368884,0.00001602108,0.0001329248,0.00003511383],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0003938081,0.00006529832,0.000394204,0.007336781,0.000207852,0.000182339,0.0000207749,0.0001513598,0.001101884,0.0006532345,0.009984819,0.9795077],"study_design_scores_gemma":[0.0005922873,0.001139851,0.01016721,0.006547332,0.00181548,0.006833733,0.0001092055,0.0004872078,0.002541915,0.002548976,0.9671492,0.00006765981],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003741162,0.9988295,0.00009825133,0.0001855178,0.0001085826,0.000002076589,0.00001326417,0.000003508995,0.0003851342],"genre_scores_gemma":[0.006383917,0.9919633,0.0002406553,0.0004520352,0.0004088503,0.000006588671,0.00005488521,0.00000237358,0.0004872884],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.001977418,"threshold_uncertainty_score":0.005654395,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07252126911291348,"score_gpt":0.3763919246789039,"score_spread":0.3038706555659905,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}